Orodispersible tablet
Orodispersible tablets (also: orodispersible tablets) are non-coated tablets , intended for ingestion. They are kept in the mouth for quick distribution before swallowing.
Orodispersible tablets are usually made by lyophilization . This comparatively complex production results in high production costs, and the lack of stability is also to be regarded as a disadvantage. Since orodispersible tablets are very hygroscopic , they are packed in special blisters (“peel-off blisters”). Opening this package can be beneficial for certain patient groups such as B. Parkinson's patients lead to difficulties.
In contrast, orodispersible tablets have some advantages over conventional tablets. According to a British study with Xilopar orodispersible tablets, 12.5% of the usual selegiline dose is sufficient to increase the concentration of the drug in the blood plasma noticeably. This is because the active ingredient in its orodispersible form is not subject to a first-pass effect .
With many other drugs, too, when the tablet dissolves in the mouth, buccal absorption occurs, which bypasses the first-pass effect. Another advantage of this dosage form is that the tablet does not have to be swallowed whole or taken with water. This improves compliance and offers advantages in the use of orodispersible tablets in pediatrics and geriatrics . Avoiding water when ingested is advantageous when using orodispersible tablets in migraine therapy, since migraine attacks are often associated with nausea.
Rapid disintegration of the orodispersible tablet in the mouth is an important prerequisite for the effect, it should take place within seconds. The European Pharmacopoeia only requires a disintegration time of a maximum of three minutes (in water).
Compared to orodispersible tablets, which are produced by lyophilization, there are more and more conventionally compressed, orodispersible tablets. These are characterized by more cost-effective production.
Well-known brand names for orodispersible tablets are, for example, Zomig , Xilopar or IMODIUM akut lingual .
Individual evidence
- ↑ a b European Pharmacopoeia, 8th edition (Ph. Eur.) . tape 1 - General part, monograph groups. Deutscher Apothekerverlag, 2014.
- ↑ a b c Conny Becker: Orodispersible drug forms. Resorbed in seconds. In: Pharmaceutical newspaper. Retrieved January 19, 2017 (edition 47/2012).
- ↑ a b Ulrike Pohl, Christian Führling, Henning Gieseler: New orodispersible tablet for migraine therapy. In: Deutsche Apothekerzeitung. Retrieved January 19, 2017 (edition 14/2012).
